Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea

 Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea

Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea

Shots:

  • The company has completed a P-I trial that assessed ALT-L9 vs Eylea in 28 patients in a ratio (1:1) with neovascular (wet) AMD. The trial was conducted at 4 major hospitals in Korea
  • The safety & efficacy of ALT-L9 were similar to Eylea and the results showed similar improvement effects in BCVA and CST. The P-I results will support the design of the P-III study and provide a path to a shorter P-III trial
  • Alteogen strengthens the competitiveness through global formulation and patents registration in the US, EU and Japan and filing of a process patent for PCT application

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post